40 Comments
 

Based on the most helpful WSO content, here’s a breakdown to help you decide:

  1. Culture:

    • Lazard: Known for a generalist program, which can be a downside for those specifically interested in RX or M&A. However, it has a strong reputation and a more traditional culture.
    • Moelis: Historically had a rougher culture with a reputation for being a "sweatshop," but recent reports suggest improvements in work-life balance, especially in the LA office. The NY office still has a facetime culture, which might not align with a preference for a more relaxed environment.
  2. Exits:

    • Lazard: Offers strong exit opportunities, particularly for M&A-focused roles. However, the generalist program might not provide the same level of specialization as other firms.
    • Moelis: The LA office is particularly strong for exits, with analysts frequently landing top-tier PE roles. The NY office also has solid exits but might not be as strong as LA.
  3. RX Focus:

    • Since you don’t care much about RX, Lazard’s generalist program might be less of a concern. Moelis has a strong RX reputation, but if RX isn’t your focus, this might not be a deciding factor.

Recommendation:
If culture and M&A-focused exits are your priority, Lazard might be the better fit. However, if you’re open to a more intense environment with strong exit opportunities, particularly in LA, Moelis could be worth considering. Ultimately, think about where you felt more comfortable during networking and interviews, as team dynamics can make a significant difference.

Sources: HL RX vs Moelis, Moelis NY in 2020? Top Groups? Exits?, Choosing RX over M&A -- anyone recommend this?, MOELIS LA SA 2021, Restructuring prospects, why you should not consider restructuring

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

ADQ sale would have been the best thing possible for Laz ironically. You know the Saudis got the pockets to get returns on their investments

 

Pretty clear that Moelis in U.S. and Lazard in Europe. You get the same opportunity in the states but Lazard seems like a sinking ship to me but that won’t matter for a few years until they actually get fucked which may or may not happen. Yeah, to be safe, I’ll just go with Moelis.

Stop monkey shitting me lazard interns. Let’s just be real. lazard rx chicago seemed to be closing their office last year. 

 
Most Helpful

Culture is Lazard. Exits is Lazard. Prestige in and out of industry is Lazard. Pay is Moelis. Moelis good bit more A2A p sure as well so would consider that too. Would say Lazard but may be biased (at my target would say Lazard is seen as a tier above). Can't make a bad decision here obviously. Best of luck!

 

Seems everyone on this forum is dead set on shitting on the Moelis brand name as much as they can.

I can tell you with certainty in industry that MOE is still highly regarded, specifically with respect to pay and exits (and particularly compared to Lazard).

Lazard is a much better place to go A2A and stay on as a career banker, but for optionally, I’d say MOE positions you better. You’re going to fucking work though. 

 

Pretty understandable why people shit on Moelis considering they ask fucking implications of section 338h10 election to summer analyst candidates and how that would differently impacted c corp vs s corp. It's a good brand but they kinda earned the hate.

 

Both great options. Obviously you can't make a "wrong" choice. Feel like this isn't that close, though, personally. To echo what some in this have pointed out, LAZ has a better brand, exits better, and has a better work environment. I think MOE is awesome and would recommend it over a lot of places, but LAZ is just...better.

 

Last thread when people voted it was like 66 moe 54 laz. It's so interesting cus u guys all look alike from cvp/evr

 

People love to try and be different when it comes to talking boutiques. Anyways, go with Lazard. As some have pointed out, it really is the obvious choice...

 

One thing people haven’t touched on is they tend to focus on somewhat different areas. Moelis rips tons of sponsor sellsides. Lazard I see more often advising corporates. Obviously both do both, but it’s sort of a tilt. There are pros and cons to each model. Especially if you want to exit to PE there’s value in having a bunch of sponsor to sponsor processes under your belt. On the other hand the experience you get on strategic/public M&A is still valuable, just comes in more flavors and you’ll probably have fewer closed deals on your CV, but the ones you do have might be more “interesting” or unusual. Source: I worked at one of their competitors that falls more in the latter camp and now on the buyside interact with both frequently in a coverage capacity. Best of luck. 

 

Qui velit optio tempora magnam cumque quasi. Omnis eius accusamus molestiae est illo modi nam. Dolores dolorum qui ab ut. Dignissimos reprehenderit unde adipisci numquam sint. Amet voluptas aut id voluptas.

Enim quam dolorum optio adipisci voluptate nesciunt. Rem ut aut id. Tempora eveniet dolores et velit culpa unde.

Ullam sunt minima voluptas accusamus et quasi. Qui ut odio ea aut deleniti sapiente voluptas voluptas. Aut nihil nam labore aut itaque nihil sint. Perferendis consequatur quia praesentium qui.

Architecto dolorem accusamus autem nostrum. Qui sunt laboriosam consequuntur quia possimus laudantium. Labore rem quod dolorum aspernatur. Voluptatem animi qui sapiente vel dolore nihil eligendi.

 

Incidunt sunt neque placeat nostrum. Voluptatem sed nobis expedita ea pariatur ut placeat. Neque autem consectetur voluptatem quos explicabo nisi vitae. Neque adipisci laudantium vel consequatur est.

Eum fuga facilis aliquam. Nostrum ipsa qui officia consequatur aliquid omnis tempore. Earum saepe quisquam totam iure iusto quos iste. Placeat iusto molestiae ut iste fuga.

Quasi sit sequi recusandae qui quis rerum qui nisi. Natus deleniti veniam natus recusandae ipsam quod.

Quo eum molestiae quisquam amet vel quos. Sit maiores quaerat autem est. Ut recusandae consequatur amet quia nesciunt explicabo. Corrupti et sunt eos perspiciatis ipsa modi. Dolorem consequuntur totam iure et eos. Quibusdam ad quia amet ut.

I don't know... Yeah. Almost definitely yes.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.2%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.2%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”